Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

<p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CM...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Mohamad Y. Khatib (11659459) (author)
مؤلفون آخرون: Karimulla S. Shaik (14777197) (author), Amna A. Ahmed (14777200) (author), Mohammad A. Alwraidat (14777203) (author), Ahmed S. Mohamed (11659456) (author), Mohamad R. Abou Kamar (14777206) (author), Mouhammad Z. Sharaf Eldean (14777209) (author), Bashar K. Aldaraiseh (14777212) (author), Abdulqadir J. Nashwan (11659453) (author)
منشور في: 2020
الموضوعات:
Biomedical and clinical sciences
Clinical sciences
Immunology
CMV reactivation
Gastrointestinal bleeding
Intestinal perforation
Tocilizumab
Immunosuppressive therapy
COVID-19
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

مواد مشابهة